Please assess the completion status of the following clinical trial:

Trial Title: Improving Right Ventricular Function in Young Adults Born Preterm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed and dated informed consent form~2. Male or female aged 18-35~3. History of preterm birth (either a or b):~   1. Participant in the Newborn Lung Project (birth year 1988-1991, birth weight \<1500 g)~  2. Non-NLP participant, with birth weight \<1500 g and gestational age 32 weeks or less, verified by medical records~Exclusion Criteria:~1. Pregnant or lactating~2. Use of prescribed medications that would interfere with study medications~   1. Sildenafil: Use of phosphodiesterase type 5 inhibitors (sildenafil, tadalafil, vardenafil), nitrates, soluble guanylate cyclase inhibitor (riociguat) within 48 hours of study visit~  2. Metoprolol: Use of nodal blocking agents including beta blockers, non-dihydropyridine calcium channel blockers (i.e. diltiazem), and anti-arrhythmics (i.e. amiodarone)~3. Presence of known comorbidities for which these therapeutic interventions would be contraindicated:~   1. Moderate to severe heart failure~  2. Severe bradycardia (heart rate \<45), or second or third-degree heart block~  3. Systolic blood pressure \<90 mmHg or \>190 mmHg~  4. Angina~  5. Severe peripheral arterial circulatory disorders~  6. History of severe bronchospasm~4. Presence of any implanted device incompatible with CMR imaging~5. Known allergic or hypersensitivity reaction to components of the study medications~6. Any other reason for which the investigator deems a subject unsafe or inappropriate for study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Sildenafil followed by Metoprolol (Type: EXPERIMENTAL): Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
- Metoprolol followed by Sildenafil (Type: EXPERIMENTAL): Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given metoprolol in between imaging scans at one visit, and will receive intravenous sildenafil in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.

Based on this trial design, predict the completion outcome and termination type (if applicable).